Bilateral optic neuritis secondary to pembrolizumab. A rare adverse event secondary to the administration of checkpoint inhibitors: A case report.
증례보고
1/5 보강
Toxicity secondary to checkpoint inhibitors (ICP) can affect numerous parts of the body, with varying frequency.
APA
Espacio Santos PM, Rabadán Márquez F, et al. (2026). Bilateral optic neuritis secondary to pembrolizumab. A rare adverse event secondary to the administration of checkpoint inhibitors: A case report.. Archivos de la Sociedad Espanola de Oftalmologia, 502503. https://doi.org/10.1016/j.oftale.2026.502503
MLA
Espacio Santos PM, et al.. "Bilateral optic neuritis secondary to pembrolizumab. A rare adverse event secondary to the administration of checkpoint inhibitors: A case report.." Archivos de la Sociedad Espanola de Oftalmologia, 2026, pp. 502503.
PMID
41881152
Abstract
Toxicity secondary to checkpoint inhibitors (ICP) can affect numerous parts of the body, with varying frequency. We present a case of bilateral optic neuritis secondary to the use of pembrolizumab (an anti-PD-1), which has been described in the literature in less than 1% of cases associated with the use of anti-PD-1/PD-L1 and anti-CTLA4 (ICP).